S&P Weighs Multibillion-Dollar Spinout of Data Unit CapIQ
THE SO WHAT
Spinning out Capital IQ Pro would turn one of S&P’s core data platforms into a pure-play asset — likely increasing competitive intensity and partnership optionality across fintech and AI. If you build on financial data, this could open new licensing structures and integration routes, but also reset pricing power in the data stack.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAm I a fake founder? What it’s like joining a startup as a cofounder a year late
Late-stage cofounders are increasingly a structural tool — a way to bolt on missing skills, credibility, or networks once the company has real signal. If you’re an early team or investor, be explicit in paper and in culture about what ‘founder’ means, or you’ll store up resentment and misaligned expectations for the first real stress event.
Startups & VentureExclusive: Legaltech Lexroom seals first two M&A deals four months after $50m Series B
Lexroom moving to M&A just four months after a $50m Series B says legaltech is consolidating into platforms, not point tools. If you’re building or buying in this category, underwrite against roll-up dynamics — either become an acquirer or design your product and contracts to be an easy plug-in for one.
Startups & VentureFirmus to Start Investor Meetings for Australia IPO, AFR Says
Firmus kicking off investor meetings for an Australian IPO is another data point that public markets are reopening selectively for tech. If you’re a late-stage company in that region, treat this as a pricing test — watch valuation multiples and demand quality before you lock in your own timing.
Startups & VentureAnthropic Said to Walk Away From $6 Billion Decart Acquisition
Walking away from a reported $6B deal is a reminder that top labs are still selective about inorganic bets — talent and IP are abundant enough that overpaying for one startup is optional. If you’re building in the AI tooling or infra layer, assume partnership and distribution deals may be more realistic than a near-term lab acquisition.